Company Filing History:
1 out of 832,966 Years Active: 2017
Title: Innovations of Ulrich Koller in Cancer Treatment
Introduction
Ulrich Koller is a notable inventor based in Neumarkt am Wallersee, Austria. He has made significant contributions to the field of cancer treatment through his innovative research and development of novel therapeutic molecules.
Latest Patents
Ulrich Koller holds a patent for an RNA trans-splicing molecule (RTM) designed for use in the treatment of cancer. This invention involves a unique pre-mRNA trans-splicing molecule that includes a binding region complementary to a pre-mRNA of a tumor-associated gene, along with a coding domain that encodes for a suicide gene. Specifically, the invention relates to RTMs that facilitate the trans-splicing of a suicide gene, such as thymidine kinase from herpes simplex virus (HSV-tk), with the pre-mRNA of the squamous cell carcinoma-associated gene solute carrier organic anion transporter family member 1B3 (SLCO1B3). The RTMs developed by Koller selectively target and kill cells expressing SLCO1B3, making them particularly useful in treating squamous cell carcinoma associated with epidermolysis bullosa. Additionally, the patent includes methods, kits, and pharmaceutical compositions related to these RTMs.
Career Highlights
Throughout his career, Ulrich Koller has worked on groundbreaking research that has the potential to change the landscape of cancer treatment. His innovative approach to utilizing RNA trans-splicing molecules showcases his commitment to advancing medical science and improving patient outcomes.
Collaborations
Ulrich Koller has collaborated with notable individuals in his field, including Johann Bauer and Christina Gruber. These partnerships have likely contributed to the development and refinement of his innovative ideas and patents.
Conclusion
Ulrich Koller is a distinguished inventor whose work in RNA trans-splicing molecules represents a significant advancement in cancer treatment. His innovative contributions have the potential to provide new therapeutic options for patients suffering from cancer.